



PRESS RELEASE

JEFF EAVES APPOINTED GENERAL MANAGER OF CIRCA SUSTAINABLE CHEMICALS UK

MELBOURNE, AUSTRALIA – 22 March 2017 – Australian biotechnology company Circa Group has appointed Dr. Jeff Eaves as General Manager of its subsidiary company, Circa Sustainable Chemicals UK Ltd., effective from 5 June 2017.

Jeff will be joining Circa Group from the University of York, where he was Industrial Liaison Manager, leading a £2.5 million European-funded contract to deliver 60 science-based projects to SMEs.

Previously CEO of technology start-up Chamelic Ltd., Jeff has worked in a variety of commercial, technical and academic roles, including for IP Group PLC, KPMG and ICI Performance Chemicals. He is also an Associate Lecturer in Business Studies at the Open University.

Tony Duncan, CEO and co-founder of Circa Group, said, “At Circa, Jeff will be focused on promoting our biosolvent Cyrene®, a non-toxic solvent produced in Tasmania from renewable, non-food biomass. With Jeff’s strong technical and commercial background, we are confident he will help us open up new markets. Circa is pleased to welcome him on board.”

-ENDS-

About Circa Group

Established in 2006, Australian company Circa Group converts waste biomass into advanced bio-based chemicals with its proprietary Furacell™ process. Circa’s broad product portfolio includes biosolvents, flavours and biopolymers, including Cyrene®, an alternative to traditional polar aprotic solvents. In 2015, Circa entered into a Joint Venture with Norwegian pulp and paper company Norske Skog to produce Cyrene® at a plant in Tasmania, Australia. Cyrene® is created through the conversion of highly-flexible platform chemical Levoglucosenone, which is also manufactured by Circa. Industrial quantities of Levoglucosenone are available for the first time thanks to Circa’s Furacell™ process and it has many industrial applications, including pharmaceutical, agrichemical, food and cleantech. By creating renewable chemicals from cellulose, Circa is extracting value from waste biomass and addressing a gap in the market by providing bio-based, non-toxic, high-performance alternatives.

